Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMD1 | P17707 | 3/20 | 0.76 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.71 |
| ▸ | DOT1L | Q8TEK3 | 5/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.64 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.64 |
| ▸ | GAPDH | P04406 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | STAT6 | P42226 | 1/20 | 0.64 |
| ▸ | PI4KA | P42356 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.64 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770046 | 1.00 | AMD1 (0.76) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL952218 | 0.94 | AMD1 (0.73) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL952217 | 0.94 | AMD1 (0.73) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL15012484 | 0.94 | AMD1 (0.73) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL30469521 | 0.89 | DOT1L (0.75) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL10664507 | 0.89 | DOT1L (0.75) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL13986400 | 0.89 | AMD1 (0.80) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL19111327 | 0.89 | AMD1 (0.80) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL954272 | 0.89 | AMD1 (0.80) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL954273 | 0.89 | AMD1 (0.80) | AMD1EZH2DOT1LDPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20210085625-A1 | CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG | PATHOLOGICA LLC | 2021-03-25 | — | — | US | disclosed |
| US-10881626-B2 | Controlled release oral pharmaceutical dosage forms comprising MGBG | PATHOLOGICA LLC (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190224144-A1 | METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING | PATHOLOGICA LLC | 2019-07-25 | — | — | US | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-10292950-B2 | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing | PATHOLOGICA LLC (US) | 2019-05-21 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180369170-A1 | METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING | PATHOLOGICA LLC | 2018-12-27 | — | — | US | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-8858991-B2 | Delayed release oral pharmaceutical dosage forms comprising MGBG | PATHOLOGICA LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8609734-B2 | Methods of treating pain with MGBG | Pathdogica, LLC (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130317113-A1 | REGULATION OF OSTEOPONTIN | PATHOLOGICA LLC (US) | 2013-11-28 | — | — | US | disclosed |
| US-8445540-B2 | Decreasing the activity of osteopontin in a cell comprising contacting the cell with an agent which inhibits S-adenosyl methionine decarboxylase, inhibits polyamine biosynthesis, or increases adenosine; MGBG, MDL73811, CGP48664, Berenil, Pentamidine, SL47, and/or SL93; autoimmune diseases; antitumor; HIV | PATHOLOGICA LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120269891-A1 | CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG | PATHOLOGICA LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-8258186-B2 | Pharmaceutical for oral delivery comprising MGBG | PATHOLOGICA, LLC (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-05-12 | — | — | US | disclosed |
| US-20080262092-A1 | REGULATION OF OSTEOPONTIN | PATHOLOGICA LLC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262092-A1 | REGULATION OF OSTEOPONTIN | ALPP, CD68, ACP3 | AMD1 2332/4885EZH2 3180/4885DOT1L 4098/4885 |
| US-20210085625-A1 | CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG | SHBG, UGGT1, GCG | AMD1 3196/4885EZH2 4875/4885DOT1L 4883/4885 |
| US-20130317113-A1 | REGULATION OF OSTEOPONTIN | ALPP, CD68, ACP3 | AMD1 2332/4885EZH2 3180/4885DOT1L 4098/4885 |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | SRM, PMP22, SMS | AMD1 6/4885EZH2 1253/4885DOT1L 2184/4885 |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | AMD1 20/4885EZH2 3221/4885DOT1L 4266/4885 |
| US-10881626-B2 | Controlled release oral pharmaceutical dosage forms comprising MGBG | SHBG, UGGT1, GCG | AMD1 3196/4885EZH2 4875/4885DOT1L 4883/4885 |
| US-20120269891-A1 | CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG | SHBG, UGGT1, GCG | AMD1 3196/4885EZH2 4875/4885DOT1L 4883/4885 |
| US-20180369170-A1 | METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING | OPRK1, PTGES3, PTGES | AMD1 4485/4885EZH2 4453/4885DOT1L 4879/4885 |
| US-20190224144-A1 | METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING | OPRK1, PTGES3, PTGES | AMD1 4485/4885EZH2 4453/4885DOT1L 4879/4885 |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | AMD1 20/4885EZH2 3221/4885DOT1L 4266/4885 |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | AMD1 20/4885EZH2 3221/4885DOT1L 4266/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | AMD1 940/4885EZH2 3355/4885DOT1L 4058/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | AMD1 940/4885EZH2 3355/4885DOT1L 4058/4885 |
| US-10292950-B2 | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing | OPRK1, PTGES3, PTGES | AMD1 4485/4885EZH2 4453/4885DOT1L 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.